Recently, molecular targeted therapies have dramatically improved the prognosis of selected advanced-stage NSCLC patients with driver mutations (e.g., epidermal growth factor receptor [EGFR]-mutant, anaplastic lymphoma kinase [ALK]-rearranged NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.